BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The European School of Multimodality Imaging & Therapy (ESMIT)
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260313T133000
DTEND;TZID=Europe/Vienna:20260313T143000
DTSTAMP:20260419T064835
CREATED:20251004T070000Z
LAST-MODIFIED:20260302T091708Z
UID:2845-1773408600-1773412200@esmit.eanm.org
SUMMARY:Radiobiological Aspects of PRRT
DESCRIPTION:This webinar will examine the fundamental differences between targeted radionuclide therapy (TRT) and conventional external beam radiotherapy (EBRT)\, integrating physical\, dosimetric\, and radiobiological perspectives relevant to clinical practice. Drawing on the EANM–ESTRO joint session\, the first part will outline how TRT’s systemic administration\, patient-specific pharmacokinetics\, protracted low dose-rate delivery\, and highly heterogeneous intratumoral distribution distinguish it from the controlled\, high dose-rate\, fractionated paradigm of EBRT. Emphasis will be placed on implications for treatment planning\, activity prescription\, imaging-based dosimetry\, and the limitations of directly translating EBRT concepts such as uniform dose coverage and standard fractionation models to TRT. \n\n\n\nThe second part will focus on how absorbed dose\, dose rate\, and spatial heterogeneity influence biological effectiveness and clinical outcomes in TRT. Key topics include sublethal damage repair during continuous irradiation\, challenges in applying conventional radiobiological models\, the impact of microscopic dose non-uniformity (especially for β- versus α-emitting therapies)\, and the relationship between local tumor control and systemic effects\, including immune modulation. The session aims to equip nuclear medicine physicians and medical physicists with a conceptual framework to interpret dosimetry results\, personalize treatments\, and critically evaluate emerging combination strategies as TRT evolves toward a quantitatively driven radiotherapy modality. \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nDifferentiate the fundamental physical and clinical characteristics of TRT versus EBRT\, including source geometry\, temporal delivery\, dose-rate profiles\, and implications for treatment planning and prescription.\n\n\n\nExplain how pharmacokinetics and biodistribution govern absorbed dose in TRT\, and why activity administration alone is an insufficient surrogate for delivered dose and therapeutic effect.\n\n\n\nAssess the impact of dose rate and protracted irradiation on radiobiological response\, including sublethal damage repair\, limitations of conventional linear-quadratic modeling\, and consequences for tumor control and normal tissue toxicity.\n\n\n\nRecognize the clinical significance of spatial dose heterogeneity at organ\, tumor\, and cellular scales\, particularly differences between β-emitting and α-emitting radiopharmaceutical therapies.\n\n\n\nInterpret the relationship between dosimetry metrics and clinical outcomes\, including local control\, toxicity\, and potential systemic (immune-mediated) effects.\n\n\n\nApply these concepts to support patient-specific dosimetry\, treatment personalization\, and multidisciplinary decision-making in modern targeted radionuclide therapy practice.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nThis webinar is intended for nuclear medicine physicians and medical physicists involved in targeted radionuclide therapy\, including early-career professionals and practitioners seeking to deepen their understanding of the physical and radiobiological principles underpinning modern TRT practice.\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nDavid Sánchez-ArtuñedoSpeaker \n\n\n\n\n\nZachary MorrisSpeaker \n\n\n\n\n\nSamantha TerryModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/radiobiological-aspects-of-prrt/
CATEGORIES:Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20260327T133000
DTEND;TZID=Europe/Vienna:20260327T143000
DTSTAMP:20260419T064835
CREATED:20251004T070000Z
LAST-MODIFIED:20260320T084326Z
UID:2847-1774618200-1774621800@esmit.eanm.org
SUMMARY:FDG PET/CT in Inflammation and Infection: from Theory to Clinical Practice!
DESCRIPTION:Imaging of infection and inflammation has been part of nuclear medicine since the 1970s. Over the past two decades\, the growing role of FDG PET/CT in diagnosing and monitoring the treatment of a wide variety of infectious and inflammatory diseases has been recognised. As a result\, this technique has recently been adopted in several clinical guidelines. This webinar provides clinical case-based evidence to assist nuclear medicine physicians in recommending\, performing and interpreting FDG PET/CT examinations in patients with infectious and inflammatory disorders. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nThe aim of this live webinar is to describe\, using illustrative clinical cases\, the role of FDG PET/CT in a variety of pathological conditions characterised by infection or inflammation\, with particular emphasis on strengths and limitations of FDG PET/CT.\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear Medicine Physicians\, Residents\, Technologists\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nAyah NawwarSpeaker \n\n\n\n\n\nDomenico AlbanoSpeaker \n\n\n\n\n\nSøren HessSpeaker \n\n\n\n\n\nLucia LeccisottiModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/fdg-pet-ct-in-inflammation-and-infection-from-theory-to-clinical-practice/
CATEGORIES:Live Webinars
END:VEVENT
END:VCALENDAR